Cost-Effectiveness Analysis of Mammography-Based Breast Cancer Screening in Indonesia

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES Value in health regional issues Pub Date : 2025-04-02 DOI:10.1016/j.vhri.2025.101112
Ajeng V. Icanervilia PhD , Keris Poelhekken MSc , Jarir At Thobari PhD , Lina Choridah PhD , Susanna H. Hutajulu PhD , Geertruida H. de Bock PhD , Maarten J. Postma PhD , Marcel J.W. Greuter PhD , Antoinette D.I. van Asselt PhD
{"title":"Cost-Effectiveness Analysis of Mammography-Based Breast Cancer Screening in Indonesia","authors":"Ajeng V. Icanervilia PhD ,&nbsp;Keris Poelhekken MSc ,&nbsp;Jarir At Thobari PhD ,&nbsp;Lina Choridah PhD ,&nbsp;Susanna H. Hutajulu PhD ,&nbsp;Geertruida H. de Bock PhD ,&nbsp;Maarten J. Postma PhD ,&nbsp;Marcel J.W. Greuter PhD ,&nbsp;Antoinette D.I. van Asselt PhD","doi":"10.1016/j.vhri.2025.101112","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The Indonesian government has not implemented mammography as national screening program. Therefore, we evaluated the cost-effectiveness of mammography-based breast cancer screening strategy in Indonesia from a societal perspective.</div></div><div><h3>Methods</h3><div>The Simulation Model on radiation Risk and breast cancer Screening was used to examine various breast cancer screening scenarios, including different screening age (40-65 vs 35-65 years), frequency (every 2, 3, 4, or 5 years), and participation rate (50%, 70%, and 100%). The model’s input parameters were independently derived from published population statistics and systematic literature.</div></div><div><h3>Results</h3><div>Our findings indicate that, across all scenarios, mammography screening was cost-effective compared with no screening under the following conditions: (1) screening women aged 40 to 65 every 4 years at 50% participation rate, (2) screening women aged 40 to 65 every 4 years at 70% participation rate, (3) screening women aged 40 to 65 every 3 years at 70% participation rate, and (4) screening women aged 40 to 65 every 2 years at 100% participation rate. The incremental cost-effectiveness ratios these scenarios compared with the next best alternative were $4758 per life year gained (US dollars/LYG), $5263/LYG, $5436/LYG, and $7569/LYG, respectively, all of which were less than 3 times Indonesia’s gross domestic product per capita.</div></div><div><h3>Conclusions</h3><div>We recommend implementing mammography screening as a national program in Indonesia. The cost-effectiveness of screening strategies depends on factors such as participation rates, screening age, frequency, and the government’s willingness-to-pay threshold. We recognize Indonesia’s competing health priorities and limited resources. Acknowledging these priorities will help policymakers in making informed decisions about resource allocation.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101112"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212109925000378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

The Indonesian government has not implemented mammography as national screening program. Therefore, we evaluated the cost-effectiveness of mammography-based breast cancer screening strategy in Indonesia from a societal perspective.

Methods

The Simulation Model on radiation Risk and breast cancer Screening was used to examine various breast cancer screening scenarios, including different screening age (40-65 vs 35-65 years), frequency (every 2, 3, 4, or 5 years), and participation rate (50%, 70%, and 100%). The model’s input parameters were independently derived from published population statistics and systematic literature.

Results

Our findings indicate that, across all scenarios, mammography screening was cost-effective compared with no screening under the following conditions: (1) screening women aged 40 to 65 every 4 years at 50% participation rate, (2) screening women aged 40 to 65 every 4 years at 70% participation rate, (3) screening women aged 40 to 65 every 3 years at 70% participation rate, and (4) screening women aged 40 to 65 every 2 years at 100% participation rate. The incremental cost-effectiveness ratios these scenarios compared with the next best alternative were $4758 per life year gained (US dollars/LYG), $5263/LYG, $5436/LYG, and $7569/LYG, respectively, all of which were less than 3 times Indonesia’s gross domestic product per capita.

Conclusions

We recommend implementing mammography screening as a national program in Indonesia. The cost-effectiveness of screening strategies depends on factors such as participation rates, screening age, frequency, and the government’s willingness-to-pay threshold. We recognize Indonesia’s competing health priorities and limited resources. Acknowledging these priorities will help policymakers in making informed decisions about resource allocation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度尼西亚基于乳房x线摄影的乳腺癌筛查的成本-效果分析
目的印尼政府尚未将乳房x光检查作为国家筛查项目实施。因此,我们从社会角度评估了印尼基于乳房x光检查的乳腺癌筛查策略的成本效益。方法采用辐射风险与乳腺癌筛查模拟模型,对不同筛查年龄(40-65岁vs 35-65岁)、频率(每2、3、4、5年一次)和参与率(50%、70%、100%)的乳腺癌筛查情景进行研究。该模型的输入参数独立来源于已发表的人口统计数据和系统文献。结果在所有情况下,与不筛查相比,乳房x光检查在以下情况下具有成本效益:(1)40至65岁女性每4年筛查一次,参与率为50%;(2)40至65岁女性每4年筛查一次,参与率为70%;(3)40至65岁女性每3年筛查一次,参与率为70%;(4)40至65岁女性每2年筛查一次,参与率为100%。与次优方案相比,这些方案的增量成本效益比分别为每生命年增加4758美元(美元/年)、5263美元/年、5436美元/年和7569美元/年,均不到印尼人均国内生产总值的3倍。结论:我们建议在印度尼西亚将乳房x线摄影筛查作为一项国家计划。筛查策略的成本效益取决于参与率、筛查年龄、频率和政府的支付意愿门槛等因素。我们认识到印度尼西亚的卫生优先事项相互矛盾,资源有限。承认这些优先事项将有助于决策者就资源分配做出明智的决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Value in health regional issues
Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
2.60
自引率
5.00%
发文量
127
期刊最新文献
How Can Mortality Trajectory Analysis Improve Health Policy and Research in Southeast Asia? Economic Evaluation and Budget Impact Analysis of Secukinumab as a Second-Line Treatment Among Patients With Psoriatic Arthritis Who Were Tumor Necrosis Factor Inadequate Responders in Thailand. Budget Impact Analysis of Fam-Trastuzumab-Deruxtecan as a Second Line in Patients With HER2-Positive Metastatic Breast Cancer in Oman Estimation of Health Utility Values for Health States in Head and Neck Cancers Using Real-World Data Table of Contents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1